HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

David Bearss Selected Research

SGI 1776

11/2009Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells.
10/2009Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


David Bearss Research Topics

Disease

10Neoplasms (Cancer)
04/2016 - 11/2002
3Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
10/2021 - 12/2017
3Prostatic Neoplasms (Prostate Cancer)
10/2009 - 09/2005
1Disease Progression
12/2017
1T-Cell Leukemia (Leukemia, T Cell)
03/2013
1Genomic Instability
03/2013
1Carcinogenesis
12/2011
1Adenocarcinoma
12/2011
1Leukemia
12/2011
1Lymphoma (Lymphomas)
12/2011
1Hemoglobinopathies
10/2010
1Glioblastoma (Glioblastoma Multiforme)
12/2009
1B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
11/2009
1Prostatic Intraepithelial Neoplasia
09/2005
1Carcinoma (Carcinomatosis)
07/2004
1Weight Gain
11/2002
1Pancreatic Neoplasms (Pancreatic Cancer)
11/2002

Drug/Important Bio-Agent (IBA)

3alvocidib (flavopiridol)IBA
10/2021 - 12/2017
3proto-oncogene proteins pimIBA
12/2011 - 10/2009
3Phosphotransferases (Kinase)IBA
11/2009 - 09/2005
2Cytarabine (Cytosar-U)FDA LinkGeneric
10/2021 - 01/2021
2Mitoxantrone (Novantrone)FDA LinkGeneric
10/2021 - 01/2021
2Pharmaceutical PreparationsIBA
03/2013 - 01/2013
2amuvatinibIBA
12/2009 - 05/2009
2Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
12/2009 - 05/2009
2SGI 1776IBA
11/2009 - 10/2009
2Proteins (Proteins, Gene)FDA Link
10/2009 - 09/2005
1Biomarkers (Surrogate Marker)IBA
10/2021
1Daunorubicin (Cerubidine)FDA LinkGeneric
01/2021
1venetoclaxIBA
12/2017
1dubermatinibIBA
04/2016
1Biological ProductsIBA
03/2013
1Immunomodulating AgentsIBA
03/2013
1Small Interfering RNA (siRNA)IBA
01/2013
1Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA
12/2011
1Janus Kinase 2IBA
12/2011
1Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
12/2011
1Fetal Hemoglobin (Hemoglobin F)IBA
10/2010
1Proto-Oncogene Proteins c-metIBA
12/2009
1Hormones (Hormone)IBA
10/2009
1Taxoids (Taxanes)IBA
10/2009
1Serine (L-Serine)FDA Link
10/2009
1Threonine (L-Threonine)FDA Link
10/2009
1taxaneIBA
10/2009
1AndrogensIBA
05/2009
1Erlotinib Hydrochloride (CP 358,774)FDA Link
05/2009
1ErbB Receptors (EGF Receptor)IBA
05/2009
1Tyrosine Kinase InhibitorsIBA
05/2009
1Type I DNA Topoisomerases (Topoisomerase I)IBA
09/2004
1PoisonsIBA
09/2004
1VaccinesIBA
07/2004
1Vitamin EFDA LinkGeneric
07/2004
1CamptothecinIBA
07/2004
1AntigensIBA
07/2004
1Cancer VaccinesIBA
07/2004
1Succinic Acid (Succinate)IBA
07/2004
1Ofloxacin (Ofloxacine)FDA LinkGeneric
11/2002
1GemcitabineFDA Link
11/2002
1Eicosapentaenoic AcidIBA
11/2002
1antigastrinIBA
11/2002
1GastrinsIBA
11/2002
1Ursodeoxycholic Acid (Urso)FDA LinkGeneric
11/2002
1TransferasesIBA
11/2002
1Capecitabine (Xeloda)FDA Link
11/2002
1Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
11/2002
1Thymidylate SynthaseIBA
11/2002
1Fish OilsIBA
11/2002
1rubitecanIBA
11/2002
1Topoisomerase I InhibitorsIBA
11/2002

Therapy/Procedure

6Therapeutics
01/2021 - 05/2009
1Radiotherapy
12/2009
1Drug Therapy (Chemotherapy)
10/2009
1Immunotherapy
07/2004
1Stents
11/2002